People diagnosed with breast cancer who may want children should discuss fertility with their cancer team early, Rochester Regional Health oncologist Rachel David says. Treatment can affect future pregnancy chances, but the options and risks vary with age, cancer type, stage and the therapies a patient needs.
The health system's updated patient guide says pregnancy remains possible for many premenopausal patients after treatment. It encourages conversations with an oncologist, obstetrician-gynecologist and reproductive endocrinologist before decisions about chemotherapy or other care are finalized.
“We discuss fertility and referral to the REI team for an assessment with all premenopausal patients, even if the patient is unclear if she desires future fertility,” David said in the guide. A referral can help people understand options without committing them to a particular procedure.
Treatment and preservation choices
Chemotherapy can damage ovarian function, though risk differs by drug, dose and patient. Egg and embryo freezing are established options that may be considered before treatment. Rochester Regional says it can refer patients to Boston IVF in Rochester for those services; it does not itself provide egg or embryo retrieval and freezing.
The American Society of Clinical Oncology's 2025 guidance recommends fertility counseling at diagnosis and during survivorship care. It recognizes barriers such as cost and insurance coverage. A patient's cancer treatment should be coordinated with fertility planning rather than delayed on the basis of a general timeline in an article.
Rochester Regional also discusses ovarian-suppression medication during chemotherapy as a possible strategy for some patients. That approach is not a guarantee of future fertility or a substitute for specialist advice. Options such as ovarian tissue preservation require individualized assessment and may not be available through the health system.
Pregnancy after treatment
Some patients with hormone receptor-positive breast cancer take endocrine therapy for five to 10 years to reduce recurrence risk. For selected patients, a planned pause to try to conceive may be discussed with the treating oncologist. The National Cancer Institute's summary of the POSITIVE trial found no increase in short-term recurrence among women who temporarily interrupted therapy after 18 to 30 months; it does not establish long-term safety for every patient or authorize stopping medication without a care plan.
People who received other treatments may face different waiting periods. The timing depends on the specific drugs, recovery, recurrence risk and pregnancy goals, not a single rule that applies to everyone. Patients who are pregnant when breast cancer is diagnosed need coordinated care from oncology and maternal-fetal medicine specialists; some treatments may be possible during pregnancy while others are not.
The central message is that family-planning questions belong in the treatment discussion from the start and can be revisited later. The guide provides general information, not a substitute for an individual medical evaluation.
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to news@fingerlakes1.com.